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We thank Dr. Kamel and colleagues for their valuable
comments [1] and would like to provide the following
response to the questions raised.
The unbound dabigatran concentration reflects the level
of active dabigatran in the blood. Administration of
idarucizumab 5 g to volunteers of various age groups and
with different degrees of renal impairment reduced
unbound dabigatran concentrations to below the lower
limit of quantitation (LLOQ) (1 ng/mL). Approximately
12–16 h post-idarucizumab administration, an increase in
the concentrations of unbound dabigatran above the LLOQ
was noted. Importantly, the underlying detection method-
ology is highly sensitive and, over the entire observation
period, levels did not increase above the threshold for
pharmacological activity. Consequently, coagulation time
measurements also did not increase above their respective
upper limits of normal, as illustrated for activated partial
thromboplastin time in Table 1.
A 5 g dose of idarucizumab completely neutralizes
dabigatran anticoagulation in almost all patients, as
demonstrated by coagulation time measurements in dabi-
gatran-treated patients receiving idarucizumab as emer-
gency treatment [2]. Coagulation time measurements are
frequently applied as routine measures in clinical emer-
gency settings, and the results can provide important
information supporting rational treatment decisions. In RE-
VERSE AD (REVERSal Effects of idarucizumab in
patients on Active Dabigatran), patients’ coagulation times
were determined up to 24 h after idarucizumab adminis-
tration [2]. In this timeframe most clinical emergencies are
expected to resolve. A re-occurrence of dabigatran anti-
coagulation was noted in some patients, mostly 12–24 h
after idarucizumab administration [2]. Importantly, almost
none of these patients were bleeding, suggesting that for
these patients the re-elevation was not clinically relevant.
However, as pointed out by Dr. Kamel and colleagues [1],
there are certain clinical situations in which a re-occurrence
of the anticoagulant effect of dabigatran might be harmful.
Consequently, a second dose of idarucizumab was allowed
in the RE-VERSE AD clinical trial; the respective data will
be available in the final publication when the trial is
complete. Consideration of an additional dose is also pro-
posed in the idarucizumab label. The criteria for the
additional dose focus on both the clinical condition of the
patient as well as the coagulation status:
• recurrence of clinically relevant bleeding together with
prolonged clotting times; or
• patients require a second emergency surgery/urgent
procedure and have prolonged clotting times [3].
Dr. Kamel and colleagues further expressed interest in
the non-renal contribution to idarucizumab elimination [1].
As this involves unspecific catabolism in the body followed
by recycling of amino acids, it is not feasible to conduct




1 Translational Medicine and Clinical Pharmacology,
Boehringer Ingelheim Pharma GmbH & Co. KG,
Birkendorfer Straße 65, 88397 Biberach an der Riss,
Germany
2 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT,
USA
3 Boehringer Ingelheim Pharma GmbH & Co. KG,
Biberach an der Riss, Germany
Clin Pharmacokinet (2017) 56:209–210
DOI 10.1007/s40262-016-0493-1
appropriate mechanistic studies to address this question
clinically. Based on our data in healthy volunteers [4, 5],
we feel confident that in healthy subjects, renal clearance is
the major pathway resulting in rapid elimination of the
drug. However, there is a dependency of idarucizumab
exposure on renal function, and under conditions of more
severe renal damage non-renal elimination pathways may
have increased relevance. We are currently analyzing our
data on renal elimination and intend to publish the results.
Finally, the value for creatinine clearance (CLCR) of
volunteers with moderate renal impairment presented in our
publication is correct. Volunteers with renal insufficiency
were enrolled into the study based on their CLCR value at the
screening visit. The value presented in the table refers to the
measurement at baseline, i.e., shortly before idarucizumab
administration. Some of the levelsmeasured at baselinewere
higher in the same individuals than those measured at
screening, explaining the discrepancy.
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Table 1 Activated partial thromboplastin time (s) [mean (standard
deviation)] values obtained 24–120 h after administration of idaru-
cizumab 5 g in volunteers with mild or moderate renal impairment,
pre-treated with dabigatran etexilate 150 mg twice daily; upper limit
of normal = 39.8 s
Group 24 h 48 h 72 h 96 h 120 h
Mild RI 32.7 (0.85) 33.0 (0.96) 30.9 (1.58) 29.6 (3.02) 30.7 (2.09)
Moderate RI 33.3 (5.64) 32.7 (4.60) 31.1 (2.21) 30.8 (2.22) 31.3 (2.75)
RI renal impairment
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